透明细胞肾癌裸鼠模型 z-bo 2021-01-04 303

　　Objective To use patient-derived clear cell renal cancer cells to establish a tumor animal model, to detect the sensitivity of ccRCC PDCs to molecular targeted drugs, and to provide theoretical and experimental basis for clinical diagnosis and treatment.

　　Methods ccRCC PDCs were inoculated subcutaneously in nude mice to establish a tumor model, and molecularly targeted drugs Sunitinib, Sorafenib, Lenvatinib, Regorafenib, and A Patinib and Anlotinib were orally administered by gavage to determine the inhibitory effect of the drugs on ccRCC PDCs in nude mice. Collect cell and tumor tissue specimens, use quantitative PCR technology to detect molecular targeted drug targets (VEGFR and other receptor tyrosine protein kinases and ERK, AKT and other protein kinases belonging to MAPK signaling pathways) to determine the inheritance of ccRCC PDCs during the experiment Whether the background remains stable.

　　Results 5 strains of ccRCC PDCs were successfully obtained, and nude mice were inoculated with the above-mentioned ccRCC PDCs to obtain a nude mouse subcutaneous tumor model of kidney cancer; in the process of culturing PDCs cells in vitro, the expression of molecular targeted drug targets, etc., decreased or lost. However, through the expansion of PDCs cells by tumor formation in nude mice, the expression of molecular targeted drugs in tumor tissues is relatively stable; the inhibitory effect of molecular targeted drugs on the subcutaneous tumor formation of ccRCC PDCs in nude mice has clear individual differences in patient origin Among the selected molecular targeted drugs, Lenvatinib's anti-tumor activity is stronger than other molecular targeted drugs.

　　Conclusion This study used patient-derived clear cell renal cancer cell lines to successfully establish an animal model of renal cancer and detect the sensitivity of renal cancer cells to molecular targeted drugs, which can provide theoretical and experimental basis for related clinical diagnosis and treatment.